2016 Annual Meeting

Society for Hematopathology

Room CC Ballroom 6 A, March 13 2016, 1:30pm to 5:00pm


Society for Hematopathology

Current Concepts in Aggressive B-Cell Leukemia/Lymphoma

Sunday, March 13, 2016
1:30 PM 5:00 PM
CC Ballroom 6A

Moderators: Eric Hsi, MD, Cleveland Clinic, Cleveland, OH
John Choi, MD, PhD, St. Jude Children’s Research Hospital, Memphis, TN

Course Description:
The Society for Hematopathology (SH) Officers and Executive Committee deliberated extensively on the selection of the 2016 USCAP/SH Companion Meeting topic and assessed need through review of prior topics, input for surveys and discussions with the SH membership, and consideration of current progress in the field to include projected updates in the WHO Classification for Hematolymphoid Neoplasms. This session will bring experts in the diagnosis, classification, and treatment of B lymphoid malignancies.
Aggressive B-cell Neoplasms are among the most common types of B-cell neoplasms in the adult (Diffuse Large B-cell Lymphoma, not otherwise specified, DLBCL, Nos) and pediatric populations (B-cell Acute Lymphoblastic Leukemia, B-ALL). Our understanding of the biology, molecular sub-classification, and clinical features of the diffuse aggressive B-cell lymphomas has advanced since the 2008 WHO Classification such that pathologists must be able to accurately diagnosis and assess molecular biomarkers, so that clinicians can appropriately risk stratify and manage patients. Likewise, diagnosis, molecular characterization, and disease monitoring for B-ALL has evolved beyond routine morphologic, phenotypic, and cytogenetic classifications. Six lectures by authorities in the field discuss the latest advances in EBV+ B-cell lymphomas (Dr. Natkunam), diagnosis of DLBCL, Nos and their related diffuse aggressive B-cell lymphomas (Dr. Medeiros), biomarker assessment for DLBCL, nos (Dr. Rimsza) and treatment of diffuse aggressive B-cell lymphomas (Dr. Leonard). These will be followed by a review of the advances in the molecular genetic classification (Dr. Mullighan) and diagnosis/monitoring (Dr. Wood) of patients with B-ALL. This balanced program addresses both lymph node and bone marrow topics that pathologists may face in daily practice.
This activity has been designed to meet the educational needs of pathologists, pathology trainees, and other health care professionals who are involved in diagnosis and management of patients with aggressive B-cell leukemias and lymphomas as well as researchers who investigate the mechanisms of these diseases.

Upon completion of this educational activity, participants should be able to:

  1. Incorporate EBV+ B-cell lymphoproliferative disorders in the differential diagnostic considerations and workup of B-cell lymphomas, and understand how to select appropriate immunophenotypic and molecular ancillary studies to support this spectrum of diagnoses.
  2. Recognize morphologic variants and subtypes of diffuse large B-cell lymphoma recognized by the World Health Organization classification.
  3. Describe the clinical significance, biology, and methodologies for measuring DLBCL cell-of-origin, oncogene, and immune/microenvironment biomarkers in order to provide precision healthcare for patients.
  4. Describe how the diagnosis of DLBCL, Nos and differentiation from other diffuse aggressive B-cell lymphomas informs prognosis, risk stratification, and treatment decisions. Participants will also become familiar with promising novel therapeutic options in these lymphomas.
  5. Discuss the different types of next generation sequencing used to analyze cancer genomes, understand the nature of genetic alterations contributing to the pathogenesis of high risk and relapsed B-ALL, and describe the potential for clinical sequencing in the management of ALL.
  6. Understand the application of modern laboratory testing to diagnose and monitor patients with B-ALL.


1:30 PM

The Spectrum of EBV+ B-cell Lymphoproliferative Disorders
Yaso Natkunam, MD, PhD, Stanford University School of Medicine, Stanford, CA

2:00 PM

Diagnosis of Diffuse Large B-cell Lymphoma
L. Jeffrey Medeiros, MD, MD Anderson Cancer Center, Houston, TX

2:30 PM

Diffuse Large B-cell Lymphoma: Biomarkers for Precision Healthcare
Lisa M. Rimsza, MD, Mayo Clinic, Phoenix, AZ

3:00 PM


3:30 PM

DLBCL, Nos from the Clinician Perspective
John P. Leonard, MD, Weill Cornell Medical College, New York, NY

4:00 PM

Advances in the Genetics of B-Cell Precursor Acute Lymphoblastic Leukemia
Charles Mullighan, MBBS, MD, St. Jude Children’s Research Hospital, Memphis, TN

4:30 PM

Diagnosis and Follow-Up of B Lymphoblastic Leukemia
Brent L. Wood, MD, PhD, Hematopathology Laboratory, Seattle, WA


view more